HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $77
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Emily Bodnar maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $70 to $77.
HC Wainwright & Co. analyst Emily Bodnar maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $70 to $77.